Multi-organ phenomic risk screening for research in Post-acute COVID Syndrome
New plasma/serum quantification package detects and quantifies 16 different metabolites and ratios thereof in the context of research in COVID and the Post-Acute COVID-19 Syndrome (PACS). It indicates the potential for providing personalized risk information related to cardiovascular disorders, Type II Diabetes, kidney disorders and the overall inflammatory status.
PhenoRisk PACS™ enables highly reproducible quantitative multiplexed testing supporting researchers in the early detection of clinically well-characterized risk markers.
PhenoRisk PACS™ is a RuO solution for Bruker’s standardized and automated Avance IVDr NMR platform enabling researchers in-depth characterization of pathomechanisms of SARS-CoV-2, even in asymptomatic individuals, thus having the potential the potential to acting as a multi-organ risk screening for organ dysfunction after SARS-CoV-2 infection in a single laboratory test.
PhenoRisk PACS™ might enables the study of SARS-CoV-2 triggered metabolic phenoconversion, defined as transient or persistent systemic change of the molecular signature in human blood after acute SARS-CoV-2 infection. Subsequent phenoreversion, indicated by normalization of the metabolic signature, can be detected by PhenoRisk PACS™ and may mark PACS recovery.
PhenoRisk PACS™ provides insight into unique (RuO) biomarkers, exclusively assessable by NMR technology (Glyc A/B, SPC) for deeper information on ongoing inflammation processes.
PhenoRisk PACS™ deepens the understanding of the multisystemic nature of SARS-CoV-2 and PACS thus supporting basic and translational clinical research as well as the development of impactful SARS-CoV-2 treatments by:
*Bruker NMR Instruments are for Research Use Only. Not for Use in Clinical Diagnostic Procedures
PhenoRisk PACS™ has the potential to help researchers with the discrimination of SARS-CoV-2 / PACS patients from healthy or recovered individuals, which could be important amongst others for translational research on new treatment approaches. This NMR-based, molecular phenomics monitoring with PhenoRisk PACS™ supports research in revealing:
Bruker’s commitment to provide customers with unparalleled help throughout the buying cycle, from initial inquiry to evaluation, installation, and the lifetime of the instrument is now characterized by the LabScape service concept.
LabScape Maintenance Agreements, On-Site On-Demand and Enhance Your Lab are designed to offer a new approach to maintenance and service for the modern laboratory